Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
Viagra Might Help To Reduce Metastasis
/in Drug repurposing, Preclinical Research/by MaxA recent study is drawing attention for a surprising reason: sildenafil, the active ingredient in Viagra, may do more than treat erectile dysfunction. Researchers reported evidence that it could also make it harder for cancer cells to spread, by interfering with the cells’ ability to access cholesterol, which appears to be important for metastasis. The […]
Blocking BCL-XL Increases ADC Effectiveness
/in Antibody-Drug Conjugate, Preclinical Research/by MaxUCLA researchers have reported a promising way to improve antibody-drug conjugates, or ADCs, in metastatic castration-resistant prostate cancer, a disease that remains difficult to control once it stops responding to hormone therapy. Their work suggests that pairing ADCs with a drug that blocks BCL-XL can make prostate cancer cells more vulnerable, leading to greater cell […]
Pluvicto Moves Into First-Line Metastatic Prostate Cancer, Marking Shift Toward Earlier Radioligand Therapy
/in Clinical Trial, FDA approvals, Metastatic, Phase 3/by MaxA new regulatory approval is reshaping the treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC), bringing radioligand therapy into much earlier stages of disease. Pluvicto (lutetium Lu-177 vipivotide tetraxetan aka 177Lu-PSMA-617), a therapy targeting prostate-specific membrane antigen (PSMA), can now be used in combination with standard androgen deprivation therapy and androgen receptor pathway inhibitors in […]
Phase 2 Trial for Xaluritamig in Patients With mCRPC and Suboptimal Response to Pluvicto
/in Clinical Trial, Metastatic, Phase 2/by MaxThomas Jefferson University is running a phase 2 study of xaluritamig, also known as AMG 509, in adults with metastatic castration-resistant prostate cancer whose disease has shown a suboptimal response to Lu-177 vipivotide tetraxetan (aka 177Lu-PSMA 617) the radioligand therapy better known as Pluvicto. The trial reflects a very specific and clinically important question: what […]
Phase 1 Trial for ASP388B
/in Clinical Trial, Metastatic, Phase 1/by MaxASP388B is an experimental anticancer drug now being tested in a first-in-human study for people with advanced solid tumors, including mCRPC. The public trial record shows it is being studied both alone and in combination with standard treatments, but its exact molecular target has not been publicly disclosed in the materials I could verify. In […]
UPDATE: FX-111 Entered Clinical Trials Phase
/in Clinical Trial, Metastatic, Phase 1/by MaxThe first-in-human Phase 1 trial is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and early signs of anti-tumor activity for FX-111 just started recruiting. We already talked about the rationale behind it in this post. FX-111 is a selective degrader of ARon, the transcriptionally active, hormone-bound form of the androgen receptor. That distinction matters because […]
Mitochondrial Fitness and Endurance May Help Men With Prostate Cancer Tolerate Androgen Deprivation Therapy Better
/in Clinical Trial, Metastatic, Non-Metastatic/by MaxA study published in Nature Communications, “Muscle mitochondria, function, mass, and quality of life in prostate cancer during androgen deprivation therapy,” looked at how muscle health affects men with advanced prostate cancer during androgen deprivation therapy. The researchers followed 60 patients over six months and assessed body composition, strength, endurance, quality of life, and skeletal […]
KAIST Strikes Again: a New Nanoparticle Platform Turns Cancer Cells into Their Own Alarm System
/in Delivery, Immunotherapy, Preclinical Research/by MaxKAIST has reported a new cancer-fighting nanoparticle platform that combines two powerful ideas into one system: helping the immune system notice cancer cells and delivering gene therapy directly into those cells. The basic concept is simple. Instead of only trying to poison or block a tumor from the outside, the nanoparticle makes the cancer cell […]